Skip to main content
Premium Trial:

Request an Annual Quote

... And Shares Climb 5 Percent After Firm Announces MassArray Add-On Launch

NEW YORK, March 16 (GenomeWeb News) - Shares of Sequenom were up 5 percent, or $.04, at $.76 in afternoon trading after the company launched two new products for the MassARRAY system.


The EpiTYPER assay for DNA methylation marker research and the QGE iPLEX multiplex assay for gene expression are commercially available and will be presented at the American Association of Cancer Research annual conference in April, said the company in a statement.


Price information was not released.


"With the launch of these new products, we are delivering on our product goals for the first quarter of 2006," said Harry Stylli, president and CEO of Sequenom.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more